Drugs / WD-910
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06897813 | Jun → Oct 2025 overdue | — | Zhejiang Wenda Pharma Technology LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WD-910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06897813 ↗ |
| Route | Oral | “Administered P.O.” NCT06897813 ↗ |